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Background: Previous studies suggest a possible association between maternal use of selective serotonin-reuptake
inhibitors (SSRIs) during early pregnancy and congenital heart defects (CHD). The purpose of this study was to verify
this association by using validated data from the Danish EUROCAT Register, and secondary, to investigate whether
the risk differs between various socioeconomic groups.
Methods: We conducted a cohort study based on Danish administrative register data linked with the Danish
EUROCAT Register, which includes all CHD diagnosed in live births, fetal deaths and in pregnancies terminated due
to congenital anomalies. The study population consisted of all registered pregnancies (n = 72,280) in Funen,
Denmark in the period 1995–2008. SSRI-use was assessed using The Danish National Prescription Registry, information
on marital status, maternal educational level, income, and country of origin from Statistics Denmark was used as
indicators of socioeconomic situation, and the CHD were studied in subgroups defined by EUROCAT. Logistic
Regression was used to investigate the association between redeemed prescriptions for SSRIs and CHD.
Results: The risk of severe CHD in the offspring of the 845 pregnant women who used SSRIs during first trimester
increased four times (AOR 4.03 (95% CI 1.75-9.26)). We found no increased risk of septal defects. Socioeconomic
position did not modify the association between maternal SSRI-use during pregnancy and severe CHD.
Conclusion: This study, which is based on data with high case ascertainment, suggests that maternal use of SSRIs
during first trimester increases the risk of severe CHD, but does not support findings from previous studies, based on
administrative register data, regarding an increased risk of septal defects. The study was unable to document an
interaction between socioeconomic status and maternal SSRI-use on the risk of severe CHD.
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The prevalence of depression is high among women in
the childbearing age [1]. Selective serotonin-reuptake
inhibitors (SSRIs) are currently the most prescribed
drugs for depression and depressive symptoms. Partly,
because some pregnancies are unplanned, and abrupt
withdrawal of SSRIs is associated with complications,
maternal use of SSRIs during pregnancies is common* Correspondence: takn@sund.ku.dk
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unless otherwise stated.[2-4]. The proportion of pregnant women in Denmark
who use SSRIs has increased by a factor eight during
the period 1997–2006 [5], and similar increases have
been observed for other countries [4,6,7]. Several stud-
ies support the evidence that users of antidepressant
tend to have lower socioeconomic status compared with
non-users of SSRIs [8-10]. Serotonin plays a role in the
early development of the heart [11]. It is therefore
plausible that maternal exposure to SSRIs can result in
congenital heart defects (CHD) in the offspring.
Recent epidemiological studies have proposed a pos-
sible association between maternal use of SSRIs duringal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ever, results for specific types of SSRIs are conflicting
[12-23], and some studies have not been able to detect
an association [24-30]. The majority of the studies have
based their information about congenital anomalies on
administrative register data, for which the validity of
these conditions is questionable and often limited to live
born children [31]. EUROCAT, a European network for
the epidemiologic surveillance of congenital anomalies,
has developed common standards for diagnosis and
registration of congenital anomalies [32]. The Danish
EUROCAT Register includes data on all pregnancy out-
comes with congenital anomalies within the Funen re-
gion of Denmark, i.e. all congenital anomalies diagnosed
in live born children, in fetal deaths and in foetuses from
pregnancies that were terminated due to foetal anomaly.
All diagnosed are verified and coded by a trained paedia-
trician [32,33]. The Danish EUROCAT Register contains
high quality data on congenital anomalies, in addition to
high case ascertainment [32]. Using data from the
EUROCAT Registry provides a good opportunity to ver-
ify and qualify previous findings in relation to the associ-
ation between SSRIs and CHD.
Some studies have shown, that CHD are more fre-
quent in the offspring of women with low socioeco-
nomic position [34-36], which may due to differences in
lifestyle factors and life conditions between socioeco-
nomic groups [37]. In a public health perspective is it
relevant to investigate whether socioeconomic status, as
an indicator for various lifestyle factors and life conditions
during pregnancy, interacts with use of SSRIs with respect
to the risk of CHD. Differences in risk may reflect differ-
ent vulnerabilities across socioeconomic groups.
The primary aim of this study was to verify the associ-
ation between maternal first trimester use of SSRIs and
CHD using the high quality anomaly data as provided by
EUROCAT (European Surveillance of Congenital Anom-
alies). We also sought to examine whether maternal so-
cioeconomic status has an influence on the association
between SSRI-use and CHD.
Methods
Study design and study population
We conducted a cohort study which included all identifi-
able pregnancies with an estimated last menstrual period
(LMP) between 2nd February 1995 and 4th October 2008
in the Funen County, Denmark. The study population
covered approximately 9% of all pregnancies in Denmark
during the same period of time. In total, 74,381 pregnan-
cies were identified through The Danish Medical Birth
Registry (live births and stillbirths) [38] and The Danish
National Hospital Register (terminations of pregnancy
and miscarriages) [39]. Information on maternal expos-
ure to SSRIs was obtained from The Danish NationalPrescription Registry [40], while the population registers
in Statistics Denmark provided data on measures for
maternal socioeconomic status [41,42]. Data from the
administrative registers were individually linked with
data from the Danish EUROCAT Register in Statistics
Denmark’s server. The Danish EUROCAT Register con-
tains information on all congenital anomalies in live
births, fetal deaths with gestational age (GA) from
20 weeks and onwards, and on all terminations of preg-
nancy after prenatal diagnosis of fetal anomaly (TOPFA).
The register covers the County of Funen from 1995 and
onwards [32]. We excluded 2,101 observations with miss-
ing data on socioeconomic measures from Statistics
Denmark. None of these were registered in EUROCAT
with congenital anomalies. The STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology)
guidelines [43] were used in preparation of the study
protocol and manuscript.
Exposure definition
The Danish National Prescription Registry contains in-
formation on sales of prescription drugs, date for sales,
specification of the medication, and drug classification
codes (the Anatomical Therapeutic Chemical (ATC)
classification system, World Health Organization) [40].
Pregnant women with redeemed prescriptions for an
SSRI during the period from 30 days before LMP
through 91 days after LMP were regarded as exposed
during first trimester. Pregnancies without a redeemed
prescription in this period were considered unexposed.
The following SSRI-preparations were examined (ATC-
codes): Fluoxetine (N06AB03), Citalopram (N06AB04),
Sertraline (N06AB06), Fluvoxamin (N06AB08), and Esci-
talopram (N06AB10), both combined and the five latter
individually. When specific preparations were examined,
pregnant women using multiple preparations of SSRIs
were excluded from the analyses.
Outcome definition
Cases with CHD were identified and verified by trained
pediatricians, who have reviewed birth and death certifi-
cates, discharge diagnosis from hospitals, post-mortem
examinations, and reports from chromosome laborator-
ies for all fetuses and children included in the study. All
CHD detected in fetuses or during the first 5 years of life
were included. Children who moved out of the County
of Funen before the diagnosis of an anomaly, were not
included in the Danish EUROCAT Register [33]. Anom-
alies were coded in ICD9 and ICD10 with the extension
from British Paediatric Association and classified accord-
ing to the EUROCAT classification in subgroups [32].
The group of severe CHD included ICD10-BPA: Q200,
Q203, Q204, Q212, Q213, Q220, Q224, Q225, Q226,
Q230, Q234, Q251, Q262 and ICD9-BPA: 74500, 74510,
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74742. Non-severe CHD included ICD10-BPA: q210,
q211, q221, q250 and ICD9-BPA: 7454, 7455, 74601,
7470. We investigated all cases with a CHD without
known associated chromosomal anomalies, genetic syn-
drome or microdeletion. Patent ductus arteriosus in pre-
term born infants were not included in EUROCAT. ASD
were included if still open six months after birth.
Socioeconomic measures
Information on maternal education from Statistics
Denmark was extracted for the year of conception.
Highest educational level was used for non-students,
while students were classified according to the educa-
tional level they would obtain after completion of their
education. Maternal education was categorized into
three groups: Women with compulsory level education
(9 years) were classified as the ‘basic’ category. Women
with medium tertiary educations, i.e. bachelors degree
education and higher were classified as the ‘higher’ cat-
egory. The remaining group were classified in the ‘inter-
mediate’ category. Information on maternal income was
derived from the year before conception and was catego-
rized in quintiles of the income for all pregnancies each
year. Maternal country of origin reflected country of birth.
The category “Western” included women from countries
in the European Union (EU) except Denmark, and from
Eastern Europe, Canada, United States, Australian, and
New Zealand. Women from other countries were included
in the category “Non-Western”. Data on marital status
was extracted as of the year of conception. For unmarried
women, the categories “singles” and “cohabiting” were de-
termined by, whether a man with an age difference of less
than 15 years who was not a blood relative lived in the
same household as the pregnant woman. Women with
registered partnerships i.e. same sex marriages were in-
cluded in the category “married”.
Statistical analyses
Maternal characteristics were compared with Pearson’s
χ2-test. The level for statistical significance was defined
as a two sided P value less than 0.05. We used Logistic
Regression to compute crude and adjusted odds ratios
(ORs) with associated 95% confidence intervals (95%
CIs) for different subgroups of CHD. Covariates exam-
ined included maternal age (≤24, 25–29, 30–34, 35–39,
≥ 40 years), years of conception (1995–1997, 1998–2001,
2002–2004, 2005–2008), and redeemed prescriptions for
antiepileptics and/or insulin from 30 days before LMP
to 91 days after (yes or no). All data on covariates were
extracted from administrative registers and were com-
plete for the study population. In order to detect any
additive interaction between maternal socioeconomic
status and SSRI-use on risk of congenital anomaly, weused Binomial Regression to calculate adjusted risk dif-
ference (RD) with associated 95% CIs.
To examine a possible confounding by indication, i.e.
that the underlying disease and not the medication
would account for any associations found, the risk of
CHD in the offspring of women who had put their treat-
ment of SSRIs on hold during pregnancy, was compared
with the risk in the offspring of unexposed women.
Women, who used SSRIs from 3–12 months before
LMP and within one year after pregnancy, but not in the
defined exposure window, were expected having a men-
tal illness without being exposed to SSRIs during preg-
nancy. Unexposed were in this case defined as women,
not treated with SSRIs from one year before to one year
after pregnancy. The study population for this sub-
analysis consisted of women with LMP between 1st
January 1996 and 4th October 2007. Moreover, the asso-
ciation between maternal SSRI exposure and CHD were
adjusted for contact with the psychiatric system within
one year before pregnancy delivered from The Psychiatric
Research Central Register [44]. Finally, we conducted a
Change-In-Estimates analysis to examine whether socio-
economic status confounded the association between ma-
ternal SSRI-use and CHD. All analyses were conducted in
the statistic software STATA (version 12.1).
Ethics
The study is a register-linkage study of routinely col-
lected data. According to Danish legislation such data
linkages have to be approved by the Danish Data Protec-
tion Agency. The national and the regional Committees
on Health Research Ethics refer to the Danish Data Pro-
tection Agency for approval of pure register-linkage
studies. The data linkages for this particular project are
approved by the Danish data Protection Agency (jr no.
2011-231-0098 and 2010-41-5082).
Results
Characteristics of the study population
Among the 72,280 pregnant women who were enrolled
in the study, a total of 845 (1.2%) had redeemed at least
one SSRI-prescription during the exposure window. The
majority had redeemed prescriptions for only one type
of SSRI (91.7%), of which Citalopram was most com-
monly redeemed (35.4%). During the study period from
1995–2008 the proportion of women who used SSRIs in-
creased by eight times. The basic characteristics of the
study population are shown in Table 1. SSRI-users dif-
fered from non-users in relation to socioeconomic pos-
ition, as they tended to be less educated, had lower
income and were more often singles. We found no sta-
tistically significant difference in relation to country of
origin. Exposed women had redeemed similar amounts
of prescriptions for SSRIs regardless of socioeconomic










1995-1997 16793 (23.51) 54 (6.39) <0.001
1998-2001 21845 (30.58) 145 (17.16)
2002-2004 15647 (21.90) 212 (25.09)
2005-2008 17150 (24.01) 434 (51.36)
Missing 0 (−) 0 (−)
Educational level
Basic 12279 (17.19) 251 (29.70) <0.001
Intermediate 34016 (47.62) 370 (43.79)
Higher 25140 (35.19) 224 (26.51)
Missing 0 (−) 0 (−)
Income group
Low 11715 (16.40) 175 (20.71) <0.001
Below average 14840 (20.77) 250 (29.59)
Average 15148 (21.21) 188 (22.25)
Above average 15100 (21.14) 125 (14.79)
High 14632 (20.48) 107 (12.66)
Missing 0 (−) 0 (−)
Country of origin
Danish 64355 (90.09) 772 (91.36) 0.337
Other Western 1818 (2.54) 22 (2.60)
Non-Western 5262 (7.37) 51 (6.04)
Missing 0 (−) 0 (−)
Marital status
Single 11701 (16.38) 254 (30.06) <0.001
Cohabiting 30812 (43.13) 328 (38.82)
Married 28922 (40.49) 263 (31.12)
Missing 0 (−) 0 (−)
Maternal age
≤ 24 years 13110 (18.35) 172 (20.36) <0.001
25-29 years 27506 (38.50) 291 (34.44)
30-34 years 22303 (31.22) 236 (27.93)
35-39 years 7507 (10.51) 120 (14.20)
≥ 40 years 1009 (1.41) 26 (3.08)
Missing 0 (−) 0 (−)
Smoking during
pregnancy
Yes 13182 (18.45) 271 (32.07) <0.001
No 51537 (72.15) 511 (60.47)
Missing 6716 (9.40) 63 (7.46)





Yes 782 (1.09) 27 (3.20) <0.001
No 70653 (98.91) 818 (96.80)
Missing 0 (−) 0 (−)
SSRI, selective serotonin-reuptake inhibitor. *χ2 test were used to calculate the
overall p value for comparison of pregnancies exposed to SSRIs in first trimester
with unexposed. Information on smoking during pregnancy and multiple
pregnancies were only available for live- and stillbirths.
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trimester were more likely to be in the youngest or oldest
age group, smokers, or to be users of antiepileptics and/or
insulin compared with non-users (Table 1). SSRI-users
and non-users did not differ with respect to plurality, pre-
vious miscarriage history, or parity (data not shown).
Maternal SSRI-use and risk of congenital heart defects
In total, we identified 546 children or fetuses with CHD
(519 live births, 12 stillbirths, 2 miscarriages, and 13 ter-
mination of pregnancy) and of these were 11 exposed to
SSRIs in the first trimester of pregnancy. Table 2 shows
that maternal exposure to any SSRI during first trimester
was associated with an increased risk of severe CHD of a
factor four. The risk estimates for the association be-
tween SSRIs and respectively Ebstein’s anomaly (AOR
35.31 (95% CI 3.21-399.43)) and hypoplastic right heart
(AOR 8.62 (95% CI 1.01-73.61)) were statistically signifi-
cant, however, the confidence intervals were very wide.
When we studied specific SSRIs, the increased risk of
CHD became statistically insignificant. After restriction
of the study population to include only live born chil-
dren, the risk estimates for the association between se-
vere CHD and respectively Citalopram and Escitalopram
became statistically significant and the risk estimates for
SSRIs overall and severe CHD were increased (data not
shown).
Table 3 presents the adjusted risk differences for se-
vere CHD between exposed and unexposed women
stratified according to socioeconomic groups. Formal
tests for interaction did not reach statistical significance,
however, the risk differences may suggest a higher risk
of severe CHD in the offspring of women exposed to
SSRIs who were cohabiting, had a basic education, and
high income.
Assessment of biases
Inclusion of maternal socioeconomic variables as covari-
ates in the multiple Logistic Regression-model resulted
in a minor (less than 10%) change of the estimated risk
Table 2 Risk of congenital heart defects among exposed to SSRIs versus unexposed
Unexposed (n = 71435) Exposed to any SSRI (n = 845)
n (%) n (%) OR (95% CI) AOR¤ (95% CI)
Congenital heart defects* 535 (0.75) 11 (1.30) 1.75 (0.96-3.19) 1.64 (0.89-3.00)
VSD 329 (17.88) 4 (16.67) 1.02 (0.38-2.76) 0.94 (0.35-2.53)
ASD 94 (5.11) 3 (12.50) 2.70 (0.85-8.55) 2.82 (0.88-9.04)
Pulmonary valve stenosis 52 (2.83) 2 (8.33) 3.26 (0.79-13.39) 3.47 (0.83-14.50)
Severe CHD 123 (0.17) 6 (0.71) 4.15 (1.82-9.44) 4.03 (1.75-9.26)
SSRI, selective serotonin-reuptake inhibitor. CHD, congenital heart defects. VSD, ventricular septal defects. ASD, atrial septal defects. NE, no estimate. OR, odds ratio. AOR,
adjusted odds ratio.
*Congenital heart defects include both non-severe and severe CHD.
Estimates are presented as ORs with 95% confidence intervals (95% CIs).
¤Multivariable Logistic Regressions are adjusted for maternal age, year of conception, use of antiepileptics and/or insulin during first trimester.
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sess a possible confounding by indication, the associ-
ation between maternal SSRI exposure and CHD were
adjusted for maternal contact with the psychiatric sys-
tem within one year before pregnancy. This adjustment
did not change the risk estimates (data not shown). Im-
portantly, we found that the offspring of women who
used SSRIs from 3–12 months before LMP and within
one year after pregnancy (4 cases), but not in the defined
exposure window, had an increased prevalence of CHD
compared with the offspring of unexposed (not using
SSRIs from one year before to one year after pregnancy)
(AOR 3.34 (95% CI 1.59-11.81)).Table 3 Risk difference of severe congenital heart defects
between exposed and unexposed stratified by
socioeconomic groups
Severe CHD (n = 129)
n (%) ARD¤ per 1,000 exposed
to SSRIs (95% CI)
Marital status
Single 25 (19.38) 1.17 (−5.71; 8.06)
Cohabiting 52 (40.31) 7.19 (−3.00; 17.37)
Married 52 (40.31) 5.71 (−4.66; 16.07)
Maternal educational level
Basic 40 (31.01) 8.42 (−4.79; 21.63)
Intermediate 53 (41.09) 4.00 (−3.49; 11.49)
Higher 36 (27.91) 3.21 (−5.76; 12.18)
Maternal income group
Low 24 (18.60) 2.90 (−6.83; 12.63)
Below average + average 55 (42.64) 4.53 (−2.93; 12.00)
Above average + high 50 (38.76) 6.80 (−4.96; 18.56)
SSRI, selective serotonin-reuptake inhibitor. CHD, congenital heart defects. ARD,
adjusted risk difference. Estimates are presented as ARD with 95% confidence
intervals (95% CIs).
¤Multivariable Binomial Regressions are adjusted for maternal age, year of
conception, and use of antiepileptics and/or insulin during first trimester.
Categories of maternal income group are combined in order to ensure, that all
categories contain exposed cases. No exposed cases had other origin than
Danish, why estimates could not be stratified in relation to country of origin.To assess the implications of misclassification, we chan-
ged the exposure window in sub-analyses: Including
women who redeemed prescriptions during the period
from three months before to three months after LMP
marginally reduced the risk estimates, while inclusion of
redeemed prescriptions only during first trimester did not
affect the estimates. Exclusion of women who redeemed
prescriptions for SSRIs 2–3 months before LMP and in
the second and third trimesters, but not in the defined ex-
posure window, i.e. with a high risk of being misclassified
as exposed, did not changes in the risk estimates.
Discussion
Main findings
In this cohort study using high quality anomaly data from
the Danish EUROCAT Register we found use of any SSRI
in the first trimester to be associated with increased risk of
severe CHD. The study lacked statistical power to docu-
ment an interaction between socioeconomic status and
maternal SSRI-use on the risk of severe CHD.
Accordance with other studies
Three previous Danish studies have found that CHD are
more prevalent in children of pregnant women who
redeemed prescriptions for SSRIs during first trimester
of pregnancy [16,18,22]. Administrative register data on
live births from The Danish National Hospital Register
formed the basis for the outcome data in these three
studies. The recent Danish nationwide cohort study of
Jimenez-Solem et al. [16] included 848,786 pregnancies
between 1997–2009. Among these pregnancies, 4,183
(0.5%) were exposed to SSRI during first trimester. Ma-
ternal exposure to any SSRI were found to be associated
with a two-fold increase in the risk of CHD overall
(AOR 2.01 (95% CI 1.60-2.53)). Several studies from
other countries have also suggested an association be-
tween maternal SSRI-use and CHD, but the results re-
garding specific types of SSRIs are conflicting [12-23].
In our study, the overall risk estimate for CHD was
close to unity and not statistically significant, but for
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significant (4.03 (1.75-9.26)). This could indicate that
SSRIs are involved in the etiology of severe CHD only.
Our findings suggest an increased risk of Ebstein’s
anomaly and hypoplastic right heart after maternal ex-
posure to SSRIs although numbers were very small (one
case with Ebstein and one with hypoplastic right heart).
Two previous studies, which have examined specific
diagnoses of CHD, have found an increased risk of right
ventricular outflow tract obstruction defects (including
Tetralogy of Fallot, transposition of great arteries, pul-
monary atresia) for paroxetine [12,19,20]. We could not
confirm the increased risk for ASD and VSD found in
studies using administrative databases [16,22]. We iden-
tified 7 different diagnoses in the 6 exposed cases with
severe CHD and this lack of specificity should lead to
cautiousness.
According to our knowledge no other published studies
have examined the association between SSRI-use and con-
genital anomalies stratified by socioeconomic groups. Un-
fortunately, this data material did not provide sufficient
statistical power to determine such an interaction, since
both the exposure and the outcome are rare events. The
estimates show opposite trends regarding the risk of se-
vere CHD in exposed with different socioeconomic posi-
tions, where different measures of socioeconomic position
were used. It is likely that these observations are due to
the great uncertainty associated with the estimates.
Strengths and limitations
The main strength of the study is the high quality of data
on congenital anomalies from the Danish EUROCAT
Register including also the most severe congenital anomal-
ies leading to fetal death and terminations of pregnancy.
The verification of anomalies diagnoses in EUROCAT re-
sults in low risk of misclassification of the outcome vari-
able and a high case ascertainment. In contrast, the
standard reporting of congenital anomalies to administra-
tive databases is associated with great risk of errors in
diagnosis coded and is often limited to diagnoses of live
born children. In particular, these databases have a ten-
dency to overestimate the prevalence of septum defects
[45]. The downside of using data from the Danish
EUROCAT Register is the limited size of the study
population, which has consequences in relation to lack
of statistical power. We examined different diagnoses of
CHD pooled in a group in order to provide sufficient
statistical power. However, grouping CHD diagnoses
with heterogeneous etiology will result in a dilution of
the studied association. When we limited the study
population to include only live births, the size of the risk
estimate for severe CHD was increased, and the associ-
ation between severe CHD and Citalopram and Escitalo-
pram respectively, became statistically significant. Thisindicates that CHD are underdiagnosed in fetal deaths
and abortions [33,46].
Although the Register of The Danish National Pre-
scription Registry includes approximately 97.5% of all
redeemed prescriptions [47] the risk of misclassification
of the exposure was significant. We have no knowledge
of when and whether the pregnant women used the
medication they had redeemed prescriptions for. Fur-
thermore, we have no information about medication
given during hospitalization. In order to verify whether
the women actually took the medication, we would have
to ask them, which was not possible in the present
study. Misclassification of the exposure variable will
probably lead to bias towards an underestimation of
SSRI’s effect. The strength, by using prescription data ra-
ther than self-reported information about SSRI-use, is
that recall bias and selection bias are eliminated. The
definition of the exposure window was based on the
average number of tablets in a package with SSRIs.
Results from a sub-analysis indicated that a broader def-
inition of the exposure variable would lead to more non-
exposed pregnancies being misclassified.
Information on covariates was obtained from Danish
administrative registers, which in general are considered
to be of high quality, limiting the extent of bias [48].
However, these registers are not designed to be used for
epidemiological studies, which is why information on
important potential confounders was not available. We
studied confounding by indication by adjusting for con-
tact with the psychiatric system. The measure’s validity
is low in relation to reflect maternal mental illness, and
the adjustment did not lead to changed risk estimates. In
accordance with findings of Jimenez-Solem et al. [16],
we found an association towards an increased risk of
CHD in the offspring of women who had used SSRIs
until 3–12 months before the pregnancy and within one
year after the pregnancy, but not in the exposure window.
Jimenez-Solem et al. [16] assumed that these women
probably have a mental illness without being exposed dur-
ing pregnancy, and the increased prevalence of CHD indi-
cates the presence of confounding by indication. However,
it is likely that women who have experienced having a
malformed child are more inclined to resume their use of
SSRIs after pregnancy, why the finding instead may be ex-
plained by differential misclassification. Published studies
which have used a comparison group of mentally ill
women treated with other antidepressants than SSRIs, find
a correlation between SSRI-use during early pregnancy
and congenital anomalies [14,25]. We are therefore less in-
clined to believe that confounding by indication plays a
major part in the association.
We adjusted for years of pregnancy, because use of
SSRIs among pregnant women have been increasing
during the study period [5], and there are an increased
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dents according to the educational level they will
achieve, when they have completed their education, be-
cause we believe, that most students share lifestyle be-
haviour and attitudes with their future colleagues.
Information on income for the year prior to conception
was used in order to prevent the pregnancy itself affect-
ing the used measure for income. It can be discussed
whether income is a valid measure of socioeconomic
status, as it classifies students who are taking a higher
education, in the lowest socioeconomic group. We
distinguished between Danish women, women from
other Western countries, and women from non-Western
countries, because we assumed that they differ in rela-
tion to lifestyle and health behaviour. However, this div-
ision is very rough and heterogeneous ethnic groups are
combined, which may have consequences in terms of re-
sidual confounding. Users of antidepressants tend to
have a lower socioeconomic status compared with non-
users, and previous studies have shown an increased
prevalence of congenital anomalies [50-52], including
CHD in the offspring of women with low socioeconomic
position [34-36]. We therefore examined the role of ma-
ternal socioeconomic status as a confounder for the as-
sociation between SSRI-use and CHD in a sub-analysis.
However, our finding did not suggest that maternal so-
cioeconomic status confounds the association.
Public health perspective of SSRI-use during pregnancy
The study’s results with respect of an association be-
tween SSRI-use and severe CHD are generalizable, but
the influence of socioeconomic status is more context-
ual. Although statistically significant, the increased risks
associated with SSRI-exposure are small in absolute
terms. We estimated that annually 4.19 severe CHD can
be prevented in the 65,439 pregnancies (which minimum
amounts to 12th gestation week in Denmark) by elimin-
ating exposure to SSRIs during first trimester. However,
use of SSRIs during pregnancy has been associated with
other adverse pregnancy outcomes e.g. miscarriages, pre-
term births, low birth weight and persistent pulmonary
hypertension [29,53-55], and we do not know the long
term consequences of exposure to SSRIs in utero. For
each pregnancy potential consequences of SSRI-use
should be weighed against the impact on the child and
the mother of an untreated mental disorder.
Conclusion
The study was not able to document whether the risk of
CHD after maternal use of SSRIs differ in various socio-
economic positions. In this study, using an optimised
case ascertainment compared to previous studies, we
found an increased risk of severe CHD with maternal
use of SSRIs during first trimester. The present studydid not support findings from previous studies where in-
formation on congenital anomalies was based on admin-
istrative data, in which an association between SSRI and
septal defects is observed.
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